抗人类免疫缺陷病毒1型广谱中和抗体的研究进展  

Progress on broadly neutralizing antibodies against human immunodeficiency virus type 1

作　　者：张子凌 刘明斌 徐建青 张晓燕 ZHANG Ziling;LIU Mingbin;XU Jianqing;ZHANG Xiaoyan(Shanghai Public Health Clinical Center Affiliated to Fudan University,Shanghai 201508,China)

机构地区：[1]复旦大学附属公共卫生临床中心

出　　处：《微生物与感染》2019年第4期252-258,共7页Journal of Microbes and Infections

基　　金：“十三五”国家科技重大专项(2017ZX10202102)

摘　　要：现行抗反转录病毒治疗药物的联合应用可有效抑制艾滋病进程并显著延长患者寿命,但由于人类免疫缺陷病毒1型(human immunodeficiency virus type 1,HIV-1)潜伏库的存在,艾滋病迄今尚无法治愈。近年发现抗HIV广谱中和抗体能有效降低患者体内病毒载量并延缓疾病进程,为研发艾滋病疫苗和治愈策略带来了曙光,尤其是序贯免疫策略的使用极大推进了广谱中和抗体的开发和应用进程。2018年,美国食品药品管理局(Food and Drug Administration,FDA)批准了第1个临床应用的广谱中性单克隆和抗体,无疑为抗HIV单克隆抗体药物的研发注入了一支强心剂。本文围绕近年来抗HIV广谱中和抗体的研究进展进行综述,探讨未来广谱中和抗体研发面临的挑战。The morbidity and mortality caused by human immunodeficiency virus type 1(HIV)/acquired immunodeficiency syndrome(AIDS)were significantly controlled through the combination of anti-HIV-1 therapy.However,HIV/AIDS still could not be cured because of the persistence of HIV-1 reservoir.The broadly neutralizing antibody(bNAb)can effectively reduce the HIV-1 viral load and slow down disease progress,which might be an effective strategy to control HIV/AIDS.The practice of sequential immune strategies has greatly promoted the development of bNAbs.In March 2018,US Food and Drug Administration(FDA)approved the first monoclonal bNAb for the treatment of adult with multidrug resistant HIV,which greatly inspired the enthusiasm for bNAb development.The present paper reviewed the research progress and challenging on bNAb development in recent years.

关 键 词：人类免疫缺陷病毒1型 广谱中和抗体 免疫策略 疫苗 

分 类 号：R51[医药卫生—内科学]